The frustrating wait for the key driver at Lexicon Pharmaceuticals (NASDAQ:LXRX)
- a clinical development and marketing partner for LX4211 - goes on.
While management spent a lot of time on its earnings call reviewing the
positive data and commercial opportunity in Type 1 diabetes, this was
all pretty well known going into the call. Management believes it can go
into Phase III development of LX4211 in Type 1 diabetes on its own, but
these shares are likely stuck unless and until a partner emerges
Follow this link to the full article:
For Lexicon Pharmaceuticals, No News Remains Bad News
No comments:
Post a Comment